Stock Details
NVO is Novo Nordisk A/S's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 86.14$. Average daily volumn in 3 months 924.1k. Market cap 212.61B



Stock symbol : NVO. Exchange : NYSE. Currency : USD
Lastest price : 92.60$. Total volume : 724.35k. Market state PRE
Click reload if you want to check the lastest price on market!!!

Novo Nordisk A/S (NVO)
Last Price
92.60$
Change
1.23
Volume
724.35k

Previous Close91.37
Open92.67
Day Range92.29-92.87
Bid0.00 x 1k
Ask0.00 x 800
Volume724.35k
Average Volume924.1k
Market Cap212.61B
Beta0.29
52 Week Range63.22-92.87
Trailing P/E31.49
Foward P/E28.06
Dividend (Yield %)1.99%
Ex-Dividend Date2021-03-26



Financial Details


According to Novo Nordisk A/S's financial reports the company's revenue in 2020 were 126.95B an increase( +3.28%) over the years 2019 revenue that were of 122.02B. In 2020 the company's total earnings were 42.14B while total earnings in 2019 were 38.95B( +10.53%).


Loading ...



Organization

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 5 countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority of its voting shares.

Novo Nordisk A/S_logo

Market Cap:
212.61B
Revenue:
126.95B
Total Assets:
144.92B
Total Cash:
12.76B


News about "Novo Nordisk A/S"

Novo Nordisk A/S – Share repurchase programme

As of 23 July 2021, Novo Nordisk has since 3 February 2021 repurchased a total of 18,020,946 B shares at an average share price of DKK 471.09 per B share equal to a transaction value of DKK ...

Source from : Yahoo Finance - 6 days ago


Daily High to Daily Low: Is It Safe to Buy Novo Nordisk A/S (NVO)?_image

Daily High to Daily Low: Is It Safe to Buy Novo Nordisk A/S (NVO)?

Novo Nordisk A/S (NYSE:NVO) went down by -0.93% from its latest closing price compared to the recent 1-year high of $88.79. The company’s stock price has collected 0.98% of gains in the last five ...

Source from : newsheater - 11 days ago


15 Most Valuable Biotech Companies in the World_image

15 Most Valuable Biotech Companies in the World

In this article we will take a look at the 15 most valuable biotech companies in the world. You can skip our detailed analysis of the biotechnology ...

Source from : Insider Monkey - 2 days ago


Here is why Novo Nordisk A/S (NVO) stock volatility recorded over the last month was 1.00%

Let’s start up with the current stock price of Novo Nordisk A/S (NVO), which is $90.40 to be very precise. The Stock rose vividly during the last session to $89.00 after opening rate of $88.48 while ...

Source from : investchronicle - 9 days ago


Novo Nordisk A/S (NVO): Hedge Funds In Wait-and-See Mode

The largest stake in Novo Nordisk A/S (NYSE:NVO) was held by Renaissance Technologies, which reported holding $1675.2 million worth of stock at the end of December. It was followed by Fisher Asset ...

Source from : Yahoo Finance - 13 days ago


Why Is Novo Nordisk Buying a Rare-Disease Candidate?_image

Why Is Novo Nordisk Buying a Rare-Disease Candidate?

Novo Nordisk is buying Prothena's ATTR cardiomyopathy program for up to $1.2 billion. While Novo is primarily known for its diabetes franchise, this isn't the company's first foray into rare diseases.

Source from : The Motley Fool - 8 days ago


Looking Closely at the Growth Curve for Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NYSE:NVO) went up by 2.87% from its latest closing price compared to the recent 1-year high of $89.00. The company’s stock price has collected 2.36% of gains in the last five trading ...

Source from : newsheater - 7 days ago


Weight-loss drug could help millions. Will they get it?

A drug that can help obese people safely cut an average of 15% of their body weight sounds like a miracle for those who can’t keep pounds off with diet ...

Source from : Daily Jefferson County Union - 12 days ago


Peptide Therapeutics Market to See Major Growth by 2031 | Lonza Inc., Novartis AG, Novo Nordisk A/S_image

Peptide Therapeutics Market to See Major Growth by 2031 | Lonza Inc., Novartis AG, Novo Nordisk A/S

The latest insightSLICE research report published on Peptide Therapeutics promises to cede reliable and clarifying insights appertaining to the real time scenario trajectory concerning the market ...

Source from : manometcurrent.com - 11 days ago


Novo Holdings Leads US$ 118M Series C Investment in Genomatica

About Novo Holdings A/S Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A ...

Source from : PR Newswire - 5 days ago


DC Circ. Won't Add To Novo Nordisk Whistleblower's Payout

Kennedy additionally claimed that Novo Nordisk instructed its sales force to provide statements ... The case is U.S. ex rel Elizabeth Kennedy et al. v. Novo A/S et al., case number 20-7062, in the U.S ...

Source from : Law360 - 9 days ago


Novo Nordisk A/S Common Stock (NVO)

©2021, EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR ...

Source from : Nasdaq - 6 days ago


Novo Holdings co-leads Hemab's US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders

Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S ...

Source from : Business Insider - 11 days ago


The Science Behind Weight | WIRED Brand Lab

Paid Content for Novo Nordisk Produced by WIRED Brand Lab | Losing weight is hard and maintaining it can be just as difficult. We sat down with Dr. Holly Lofton of NYU's Grossman School of ...

Source from : Wired - 11 days ago


Hemab Raises US$ 55M in Series A Funding

Based in Denmark and the US, the company has exclusive licenses to antibody technologies from both Novo Nordisk A/S and Genmab A/S. Hemab aims to progress its pipeline of monoclonal and bispecific ...

Source from : finsmes.com - 11 days ago


Novo Nordisk A/S (NVO): Hedge Funds In Wait-and-See Mode

In this article you are going to find out whether hedge funds think Novo Nordisk A/S (NYSE:NVO) is a good investment right now. We like to check what the smart money thinks first before doing ...

Source from : Insider Monkey - 13 days ago


Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 26 July 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 ...

Source from : Yahoo Finance - 7 days ago


Weight-Loss Drug Could Help Millions. Will They Get It?

Wegovy, a Novo Nordisk A/S drug that the Food and Drug Administration approved in early June, appears to do exactly that. It helps people lose substantially more weight than with existing drugs and ...

Source from : BloombergQuint - 14 days ago


Novo Nordisk A/S Share repurchase programme

With the transactions stated above, Novo Nordisk owns a total of 16,344,444 B shares of DKK 0.20 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares ...

Source from : Middle East North Africa Financial Network - 14 days ago


Novo Nordisk A/S – Share repurchase programme

With the transactions stated above, Novo Nordisk owns a total of 16,344,444 B shares of DKK 0.20 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares in ...

Source from : Privata Affärer - 14 days ago


Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 5 July 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council ...

Source from : Yahoo - 28 days ago


Novo Nordisk A/S Series B

Helge Lund Chairman The International Crisis Group (United States), Belron Group SA, Novo Nordisk A/S, International Crisis Group, Tjaldur P/F, BP Plc, Inkerman Holding AS Elizabeth Anne Hewitt ...

Source from : Wall Street Journal - 5 days ago


Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 5 July 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 ...

Source from : Yahoo Finance - 28 days ago


Novo Nordisk A/S ADR

Helge Lund Chairman The International Crisis Group (United States), Belron Group SA, Novo Nordisk A/S, International Crisis Group, Tjaldur P/F, BP Plc, Inkerman Holding AS Elizabeth Anne Hewitt ...

Source from : Wall Street Journal - 6 days ago


Novo Nordisk A/S Share repurchase programme

With the transactions stated above, Novo Nordisk owns a total of 15,247,509 B shares of DKK 0.20 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares ...

Source from : Middle East North Africa Financial Network - 27 days ago


Novo Nordisk A/S – Share repurchase programme

With the transactions stated above, Novo Nordisk owns a total of 15,247,509 B shares of DKK 0.20 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares ...

Source from : wallstreet online - 28 days ago


Novo Nordisk A/S – Share repurchase programme

With the transactions stated above, Novo Nordisk owns a total of 15,794,444 B shares of DKK 0.20 as treasury shares, corresponding to 0.7% of the share capital. The total amount of A and B shares in ...

Source from : Privata Affärer - 21 days ago


Prothena and Novo Nordisk announce acquisition agreement for Prothena’s ATTR amyloidosis programme

Prothena Corporation plc and Novo Nordisk A/S today announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage ...

Source from : PharmiWeb - 20 days ago